| Product Code: ETC6004133 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview |
3.1 Afghanistan Country Macro Economic Indicators |
3.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, 2021 & 2031F |
3.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Industry Life Cycle |
3.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Porter's Five Forces |
3.5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.7 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about chronic inflammatory demyelinating polyneuropathy (CIDP) among healthcare professionals and patients. |
4.2.2 Rising prevalence of autoimmune disorders in Afghanistan leading to a higher incidence of CIDP cases. |
4.3 Market Restraints |
4.3.1 Limited access to advanced diagnostic tools and treatments in Afghanistan. |
4.3.2 Challenges related to affordability and reimbursement for CIDP treatments in the country. |
5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends |
6 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Types |
6.1 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous Immunoglobulin, 2021- 2031F |
6.1.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.1.5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Plasmapheresis, 2021- 2031F |
6.1.6 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Physiotherapy, 2021- 2031F |
6.1.7 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Diagnosis |
6.2.1 Overview and Analysis |
6.2.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Electrodiagnostic Testing, 2021- 2031F |
6.2.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Nerve Conduction, 2021- 2031F |
6.2.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By EMG, 2021- 2031F |
6.2.5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Spinal Fluid Analysis, 2021- 2031F |
6.2.6 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.3.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.5.5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
7 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Import-Export Trade Statistics |
7.1 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Export to Major Countries |
7.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Imports from Major Countries |
8 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Key Performance Indicators |
8.1 Average time from symptom onset to diagnosis of CIDP in Afghanistan. |
8.2 Number of neurologists specializing in CIDP in Afghanistan. |
8.3 Percentage of CIDP patients receiving recommended treatment according to international guidelines. |
8.4 Patient-reported outcomes and quality of life improvements post-treatment for CIDP in Afghanistan. |
8.5 Availability and utilization rates of CIDP-specific support services in the country. |
9 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Opportunity Assessment |
9.1 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.3 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Competitive Landscape |
10.1 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue Share, By Companies, 2024 |
10.2 Afghanistan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here